Table of Contents
Up to half of all people who sustain a concussion will carry its effects long after the initial injury fades, living with headaches, dizziness, cognitive fog, irritability, and disrupted sleep that can persist for months or years. There are few proven therapies for this condition, and many patients are left managing symptoms without meaningful relief. Researchers at Monash University in Melbourne now believe psilocybin, the naturally occurring compound found in certain mushrooms, may offer a new path forward, and they have launched Australia’s first clinical trial to find out.
What the Trial Is Testing
The study is a randomized, double-blind, active placebo-controlled clinical trial, the most rigorous design available in human research. It will enroll participants who have experienced persistent post-concussion symptoms for at least six months, regardless of how the original concussion occurred. The trial will run over three years beginning in 2026, with sessions taking place in Melbourne. Lead researcher Professor Terence O’Brien, head of Monash’s School of Translational Medicine, described the trial as a significant step forward for a patient population that has lacked effective options. “In addition to alleviating symptoms, research suggests it can also target the biological effects concussion has on the brain,” O’Brien said.
The Biological Rationale: Neuroinflammation and Neural Plasticity
The trial draws on a preclinical study from Monash University, published in the journal Cell Reports Medicine, which found that a single macrodose of psilocybin reduced symptoms associated with brain injury in animal models. Professor Sandy Shultz, from the Monash Trauma Group, explained that researchers expect psilocybin to reduce neuroinflammation and enhance the brain’s capacity to form new neural connections, a quality sometimes described as neuroplasticity. The team will collect blood samples and neuroimaging biomarkers throughout the trial to track precisely how the compound acts within the body and brain. Shultz noted that any symptom benefits could persist for at least six months after treatment, a possibility the trial is specifically designed to test.
How Participants Are Supported
Dr. Josh Allen, a research fellow in the Clinical Psychedelic Lab at Monash’s School of Clinical Sciences, emphasized that participants are not simply administered a substance and observed. The protocol includes preparation sessions before the psychedelic experience, guided care during the session itself, and integration therapy afterward. “Our approach will promote safety and maximize benefits for all trial participants,” Allen said. Dr. Paul Liknaitzky, head of the Clinical Psychedelic Lab, described the method as a combined treatment targeting both the neurological and psychological dimensions of patients’ symptoms. This dual focus, addressing the brain’s biology alongside the person’s inner experience, is central to how the team understands psilocybin-assisted therapy.
The Collaboration Behind the Research
The project unites Monash University’s Department of Neuroscience and Department of Psychiatry, and extends to researchers at Deakin University, the University of Queensland, and Connectivity Traumatic Brain Injury Australia. The breadth of the collaboration reflects the multi-disciplinary nature of the problem: concussion is not purely neurological, nor purely psychological, and the researchers are approaching it on both fronts simultaneously. It is worth noting that the preclinical findings that informed this trial are hypothesis-generating, not proof of efficacy in humans. The clinical trial now underway is the necessary next step to determine whether those early results translate to people living with persistent post-concussion symptoms.
When the Brain Cannot Heal Alone
Concussion sits in a strange space in medicine: an injury that is real and often debilitating, yet frequently dismissed because it leaves no visible wound. The people who carry persistent symptoms for months or years often carry something else too, a quiet doubt that their suffering is taken seriously. This trial is, among other things, an act of recognition.
What draws us to this research is the wholeness of its design. Psilocybin is not being handed to participants as a pill and a waiting room. The protocol includes preparation, guided presence, and integration, the same arc that contemplative traditions have always known: you enter, you move through, you return and make meaning of what you found. The researchers call it addressing neurological and psychological drivers together. We might call it tending to both the vessel and the one who lives inside it.
The preclinical data are promising, and we hold that honestly: animal studies are not human outcomes. But the willingness to bring rigorous science into conversation with a compound that has been used ceremonially for centuries, and to do so with genuine care for participant safety, points toward something worth paying close attention to.
If this research speaks to something you or someone you love has carried, we invite you to sit with it, not as a cure announced, but as a question being asked with care. The Golden Path station of Awakening asks us to remain open to what we do not yet fully understand. Come into our community spaces and share what arises.
May love guide the hearts of all beings.
